Literature DB >> 21970662

Therapy for ocular toxoplasmosis.

Alejandra de-la-Torre1, Miles Stanford, Andre Curi, Glenn J Jaffe, Jorge E Gomez-Marin.   

Abstract

PURPOSE: To review current evidence for the treatment of ocular toxoplasmosis (OT).
DESIGN: Narrative review and expert recommendations.
METHODS: Meta-analysis and selected original articles from the medical literature were reviewed critically. Expert recommendations were analyzed.
RESULTS: Numerous observational studies suggest a benefit of short-term antimicrobial therapy for toxoplasmic retinochoroiditis in immunocompetent patients, although its efficacy has not been proven in randomized clinical trials. A randomized clinical trial revealed that intermittent trimethoprim/sulfamethoxazole treatment could decrease the rate of recurrence in high-risk patients. Intravitreal injection of clindamycin and dexamethasone was an acceptable alternative to the classic treatment for OT in a randomized clinical trial.
CONCLUSIONS: Opinions about therapy differ and controversy remains about its type, efficacy, and length. Intravitreal therapy may be promising for OT. A recent description of the presence of parasitemia in patients with active and inactive ocular toxoplasmosis raises new questions that need to be explored.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970662     DOI: 10.3109/09273948.2011.608915

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  15 in total

1.  Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy.

Authors:  Jili Zhang; Hongfei Si; Kun Lv; Yanhua Qiu; Jichao Sun; Yubin Bai; Bing Li; Xuzheng Zhou; Jiyu Zhang
Journal:  Front Cell Dev Biol       Date:  2021-06-11

2.  An evidence-based medicine audit of the ophthalmic emergency services unit of King Abdulaziz University Hospital (KAUH).

Authors:  Adel Alsuhaibani; Mohammed AlRajeh; Priscilla Gikandi; Ahmed Mousa
Journal:  Int Ophthalmol       Date:  2017-10-10       Impact factor: 2.031

3.  Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.

Authors:  Konstantinos Balaskas; Jean Vaudaux; Noémie Boillat-Blanco; Yan Guex-Crosier
Journal:  Med Sci Monit       Date:  2012-05

4.  Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis.

Authors:  Lana Tamaddon; S Abolfazl Mostafavi; Reza Karkhane; Mohammad Riazi-Esfahani; Farid Abedin Dorkoosh; Morteza Rafiee-Tehrani
Journal:  Adv Biomed Res       Date:  2015-01-30

5.  A prospective randomized trial of azithromycin versus trimethoprim/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis.

Authors:  Alireza Lashay; Ahmad Mirshahi; Najaf Parandin; Hamid Riazi Esfahani; Mehdi Mazloumi; Mohammad Reza Lashay; Mohammad Karim Johari; Elham Ashrafi
Journal:  J Curr Ophthalmol       Date:  2016-12-28

6.  Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the Vizient Health Systems Data from 2011 to 2017.

Authors:  Kathy Belk; Mark P Connolly; Lisa Schlesinger; Ruben R Ben-Harari
Journal:  Pathog Glob Health       Date:  2018-12-10       Impact factor: 2.894

Review 7.  Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis.

Authors:  John E Feliciano-Alfonso; Juliana Muñoz-Ortiz; María Alejandra Marín-Noriega; Andrés Vargas-Villanueva; Laura Triviño-Blanco; Natalia Carvajal-Saiz; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-07-19

8.  A typical bilateral Toxoplasma retinochoroiditis in a bone marrow transplant patient with negative serum titers.

Authors:  Albert Hazan; Rakesh M Patel; David Levinson; Umar Mian; David C Gritz
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-28

Review 9.  Clinical features and treatment of ocular toxoplasmosis.

Authors:  Young-Hoon Park; Ho-Woo Nam
Journal:  Korean J Parasitol       Date:  2013-08-30       Impact factor: 1.341

10.  Neglected parasitic infections in the United States: toxoplasmosis.

Authors:  Jeffrey L Jones; Monica E Parise; Anthony E Fiore
Journal:  Am J Trop Med Hyg       Date:  2014-05       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.